



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington DC 20231 on

MERZ 30/dln

Applicants

Christopher G. R. PARSONS, et al.

Title

1-AMINO-ALKYLCYCLOHEXANES AS 5-HT, AND

NEURONAL NICOTINIC RECEPTOR ANTAGONISTS

Serial No.

09/597,102

Filing Date

20 JUN 2000

Art Unit

1617

Examiner

Shaojia JAING, Ph.D.

RECEIVED AUG 1 2 2003

OFFICE OF PETITIONS

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

STATUS INQUIRY AND SUBMISSION OF COPY OF RESPONSE

Sir:

A Final Rejection dated 05 JUN 2002 was received by the undersigned attorney. In response thereto, a Response and Amendment After Final was submitted to the Patent Office on 03 AUG 2002 and was received in the Patent Office on 12 AUG 2002.

A status check through the PAIR system reveals that this Response has not been entered into the record of this application even though a later drawings submission has been. The Patent Office is respectfully requested to check the status of this Response.

In view of the above circumstances, a copy of the Response and Amendment

After Final, along with a copy of the return post card showing receipt by the

Patent Office, are enclosed for the convenience of the Examiner.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

G. PATRICK SAGE, Attorney #37,710

Dated: February 11, 2003 Customer No. 25,666 500 Columbia Plaza 350 East Michigan Avenue Kalamazoo, MI 49007 (616) 382-0030

RECEIVED


AUG 1 2 2003

OFFICE OF PETITIONS

Enclosure: Return Postal Card Receipt

Copy of Response and Amendment After Final

Copy of return post card



RECEIVED

AUG 1 2 2003

OFFICE OF PETITIONS

Applicants

Title

Christopher G. R. PARSONS, et al.

1-AMINO-ALKYLCYCLOHEXANES AS

5-HT₃ AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS

09/597,102

Serial No.

20 JUN 2000

Filing Date

1617

Art Unit

Shaojia JAING, Ph.D.

Examiner

Status inquiry with copy of Response and Amendment after Final and copy of return post card receipt.

MERZ 30/dln

February 11, 2003

Applicants

Title

Christopher G. R. PARSONS, et al. 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3 AND NEURONAL NICOTINIC

Serial No. Filing Date

Art Unit Examiner

RECEPTOR ANTAGONISTS 09/597,102 20 JUN 2000

1617

Shaojia JAING, Ph.D.

Status inquiry with copy of Response and Amendment after Final and copy of return post card receipt. MERZ 30/dln February 11, 2003

PE	Application No.	Applicant(s)			
		1			
Advisory Action	09/597,102	PARSONS ET AL.			
AUVISON Y AUTON 1 1 2003	Examiner	Art Unit			
	Shaojia A. Jiang	1617			
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence address			
THE REPLY FILED 10 September 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR REPLY [check either a) or b)]					
a) The period for reply expires 4 months from the mailing date	of the final rejection. June 5, 200	Dec 5, 2002			
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2.⊠ The proposed amendment(s) will not be entered be	, ,,,	appoon			
(a) ☐ they raise new issues that would require furthe	r consideration and/or search (s	ee NOTE below):			
(b) they raise the issue of new matter (see Note below);					
(c) ⊠ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceling	g a corresponding number of fir	nally rejected claims.			
NOTE: see attachemnt.					
3. Applicant's reply has overcome the following rejection(s):					
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).					
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attachment.					
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.					
7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.					
The status of the claim(s) is (or will be) as follows:		RECEIVED			
Claim(s) allowed: <u>none</u> .		, NUC 1 2 2002			
Claim(s) objected to: <u>none</u> .		/ AUG 1 2 2003			
Claim(s) rejected: <u>1-17</u> .		OFFICE OF PETITIONS			
	Claim(s) withdrawn from consideration: <u>none</u> . 8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.				
	• •	oved by the Examiner.			
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s). 10. Other:					
		ENI PADMANABHAN S/18/05			
U.S. Patent and Trademark Office					

Application/Control Number: 09/597,102

Art Unit: 1617

Advisory Action

This Office Action is a response to Applicant's amendment and response <u>after</u>

FINAL filed on September 10, 2002 (a copy by Fax filed on March 3, 2003).

- 2. Applicant's proposed amended claim, deleting "anxiety disorderes, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease" and "Parkinson's disease, Tourette's pain" from the original claim, are not deemed to place the application in better form for appeals by materially reducing or simplifying the issues for appeal, as discussed further below.
- 5. Applicant's remarks filed on September 10, 2002 with respect to the rejection of claims 1-17 made under 35 U.S.C. 102(e) as being anticipated by Gold et al. (WO 99/01416) have been fully considered but are unpersuasive for reasons of record stated in the Final Office Action dated June 5, 2002.

As discussed in the Final Rejection, Gold et al. disclose that the same 1aminoalkylcyclohexanes as herein are useful in the treatment of CNS disorders or a
living animal for alleviation of a condition which is alleviated by the NMDA receptor
antagonists. The instant claims 1-17 are drawn to a method of treating a living animal
for inhibition of progression or alleviation of a condition which is alleviated by a 5HT3 or
neuronal nicotinic receptor antagonist such as emesis, crebellar trenor, and appetite
disorders (see the instant claim 1) comprising same compounds herein. Therefore, the
teachings of Gold et al. would be inherent in the instant claimed methods See *Ex parte*

Page 2

Novitski 26 USPQ 2d 1389. Note that the amount of active compounds to be administered in instant invention is same as in Gold et al.

Even though Applicant's proposed amendment deleted "anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease" and "Parkinson's disease, Tourette's pain" from the original claims, the proposed amended claims are still seen to be anticipated by Gold et al. under the doctrine of inherency. See *Eli Lilly and Co. v. Barr Laboratories Inc.* 251 F3d. 955; 58 USPQ2d 1869-1881 (Fed. Cir. 2001).


Therefore, Gold et al. anticipates the instant claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, Ph.D., can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D. Patent Examiner, AU 1617 March 17, 2003





Application No.	Applicant(s) PARSONS ET AL.		
09/597,102			
Examiner	Art Unit		
Shaojia A. Jiang	1617		

	Shaojia A. Jiang	1617				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address-						
This application is abandoned in view of:						
 Applicant's failure to timely file a proper reply to the Office (a) A reply was received on (with a Certificate of M period for reply (including a total extension of time of) (b) A proposed reply was received on <u>12 August 2002</u>, but rejection. 	ailing or Transmission dated month(s)) which expired on	·	•			
(A proper reply under 37 CFR 1.113 to a final rejection application in condition for allowance; (2) a timely filed Continued Examination (RCE) in compliance with 37 C	Notice of Appeal (with appeal fee); of					
(c) A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the non-final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).						
(d) ☐ No reply has been received.						
 Applicant's failure to timely pay the required issue fee and from the mailing date of the Notice of Allowance (PTOL-85) 		the statutory period	of three months			
 (a) The issue fee and publication fee, if applicable, was), which is after the expiration of the statutory pe Allowance (PTOL-85). 	received on (with a Certification for payment of the issue fee (an	te of Mailing or Tra d publication fee) s	ansmission dated et in the Notice of			
(b) The submitted fee of \$ is insufficient. A balance	of \$ is due.					
The issue fee required by 37 CFR 1.18 is \$ T	he publication fee, if required by 37 (CFR 1.18(d), is \$	·			
(c) \square The issue fee and publication fee, if applicable, has no	been received.					
 Applicant's failure to timely file corrected drawings as requi Allowability (PTO-37). 	red by, and within the three-month p	eriod set in, the Not	tice of			
(a) ☐ Proposed corrected drawings were received on after the expiration of the period for reply.	(with a Certificate of Mailing or Trans	smission dated), which is			
(b) \(\sum \) No corrected drawings have been received.						
I. The letter of express abandonment which is signed by the the applicants.	attorney or agent of record, the assiç	gnee of the entire in	iterest, or all of			
 The letter of express abandonment which is signed by an an analysis. 1.34(a)) upon the filing of a continuing application. 	attorney or agent (acting in a represe	entative capacity un	der 37 CFR			
 The decision by the Board of Patent Appeals and Interfere of the decision has expired and there are no allowed claim 		the period for seek	king court review			
7. The reason(s) below:	CEÍVED	0	ll.			
/ AL	IG 1 2 2003 SREEN	II PADMANABHAN	(Sh.)			
	PRIN	MARY EXAMINER	47/03			
OFFIC	E OF PETITIONS		1 (

Petitions to revive under 37 CFR 1.137(a) or (b), or requests to withdraw the holding of abandonment under 37 CFR 1.181, should be promptly filed to minimize any negative effects on patent term.

U.S. Patent and Trademark Office
PTO-1432 (Rev. 04-01)

Notice of Abandonment

Part of Paper No. 17

0/8	Application No.	Applicant(s)				
Advisory Action 4	09/597,102	PARSONS ET AL.				
Advisory Action	\ <u> </u>	Art Unit				
	Shaojia A. Jiang	1617				
-The MAILING DATE of this communication for	pears on the cover sheet w	ith the correspondence address -				
THE REPLY FILED 12 August 2002 FAILS TO PLACE Therefore, further action by the applicant is required to final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	ETHIS APPLICATION IN (avoid abandonment of this (1) a timely filed amendme	CONDITION FOR ALLOWANCE. s application. A proper reply to a ent which places the application in				
PERIOD FOR F	REPLY [check either a) or	b)]				
a) The period for reply expires 3 months from the mailing da						
b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WA 706.07(f).	e later than SIX MONTHS from t AS FILED WITHIN TWO MONTH	he mailing date of the final rejection. HS OF THE FINAL REJECTION. See MPEP				
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Of timely filed, may reduce any earned patent term adjustment. See 37	I of extension and the correspon of the shortened statutory period ffice later than three months afte	ding amount of the fee. The appropriate extension for reply originally set in the final Office action; or				
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) they raise new issues that would require furth	(a) they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal b	y materially reducing or simplifying the				
(d) they present additional claims without cance	ling a corresponding numb	per of finally rejected claims.				
NOTE: <u>See attachment</u> .						
3. Applicant's reply has overcome the following rejection	tion(s):					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	d be allowable if submitted	in a separate, timely filed amendment				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See attachment</u> .						
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	cause it is not directed SO	LELY to issues which were newly				
7. ☐ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:		RECEIVED				
Claim(s) allowed: <u>none</u> .						
Claim(s) objected to: <u>none</u> .		AUG 1 2 2003				
Claim(s) rejected: <u>1-17 (all)</u> .		OFFICE OF PETITIONS				
Claim(s) withdrawn from consideration: <u>none</u> .						
	3. The proposed drawing correction filed on is a) \square approved or b) \square disapproved by the Examiner.					
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						
		RUSEFIA TRAVERS PRIMARY EXAMINER GROUP 1200				
U.S. Patent and Trademark Office						

Application/Control Number: 09/597,102

Art Unit: 1617

Advisory Action

This Office Action is a response to Applicant's amendment and response <u>after</u> FINAL filed on August 12, 2002.

- 2. Applicant's proposed amended claim, <u>deleting</u> "anxiety disorderes, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease" and "Parkinson's disease, Tourette's pain" from the original claim, present a new issue for search and consideration by the Examiner,
- 5. Applicant's remarks filed August 12, 2002 with respect to the rejection of claims 1-17 made under 35 U.S.C. 102(e) as being anticipated by Gold et al. (WO 99/01416) have been fully considered but are unpersuasive for reasons of record stated in the Final Office Action dated June 5, 2002.

As discussed in the Final Rejection, Gold anticipates the claimed invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (703) 305-1008. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Russell S. Travers, J.D., Ph.D, can be reached on (703) 308-4603. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Application/Control Number: 09/597,102

Art Unit: 1617

Page 3

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Shaojia A. Jiang, Ph.D. Patent Examiner, AU 1617 August 19, 2002